[go: up one dir, main page]

BRPI0810471A2 - Produtos de glicoproteína definidos e métodos relacionados - Google Patents

Produtos de glicoproteína definidos e métodos relacionados

Info

Publication number
BRPI0810471A2
BRPI0810471A2 BRPI0810471-9A2A BRPI0810471A BRPI0810471A2 BR PI0810471 A2 BRPI0810471 A2 BR PI0810471A2 BR PI0810471 A BRPI0810471 A BR PI0810471A BR PI0810471 A2 BRPI0810471 A2 BR PI0810471A2
Authority
BR
Brazil
Prior art keywords
related methods
glycoprotein products
defined glycoprotein
products
methods
Prior art date
Application number
BRPI0810471-9A2A
Other languages
English (en)
Inventor
Ganesh Venkataraman
Brian Edward Collins
Carlos J Bosques
Lakshammanan Thiruneelakantapillai
Dorota A Bulik
Ian Christopher Parsons
Zachary Schriver
Rajeev Chilakuru
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of BRPI0810471A2 publication Critical patent/BRPI0810471A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00ICT programming tools or database systems specially adapted for bioinformatics

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Databases & Information Systems (AREA)
  • Biophysics (AREA)
  • Bioethics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0810471-9A2A 2007-04-16 2008-04-15 Produtos de glicoproteína definidos e métodos relacionados BRPI0810471A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91210207P 2007-04-16 2007-04-16
PCT/US2008/060354 WO2008128227A1 (en) 2007-04-16 2008-04-15 Defined glycoprotein products and related methods

Publications (1)

Publication Number Publication Date
BRPI0810471A2 true BRPI0810471A2 (pt) 2014-11-11

Family

ID=39553226

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810471-9A2A BRPI0810471A2 (pt) 2007-04-16 2008-04-15 Produtos de glicoproteína definidos e métodos relacionados

Country Status (12)

Country Link
US (2) US20100113294A1 (pt)
EP (2) EP2137655B1 (pt)
JP (1) JP2010524467A (pt)
CN (1) CN101681396A (pt)
AU (1) AU2008240080A1 (pt)
BR (1) BRPI0810471A2 (pt)
CA (1) CA2682738A1 (pt)
ES (1) ES2389618T3 (pt)
PL (1) PL2137655T3 (pt)
PT (1) PT2137655E (pt)
RU (1) RU2009141965A (pt)
WO (1) WO2008128227A1 (pt)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
RU2518289C2 (ru) 2006-09-13 2014-06-10 Эббви Инк, Способ получения антитела или его фрагмента с подпиткой (варианты)
NZ592097A (en) 2008-10-20 2013-01-25 Abbott Lab Viral inactivation during purification of il-12 and il-18 antibodies
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
EP2325296A1 (en) * 2009-11-20 2011-05-25 LEK Pharmaceuticals d.d. Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
AU2011237445B2 (en) * 2010-04-07 2016-03-24 Momenta Pharmaceuticals, Inc. Selection and use of host cells for production of glycoproteins
US9921210B2 (en) 2010-04-07 2018-03-20 Momenta Pharmaceuticals, Inc. High mannose glycans
EP2686671A4 (en) 2011-03-12 2015-06-24 Momenta Pharmaceuticals Inc N-GLYCANES CONTAINING N-ACETYLHEXOSAMINE IN GLYCOPROTEIN PRODUCTS
EP2511293A1 (en) 2011-04-13 2012-10-17 LEK Pharmaceuticals d.d. A method for controlling the main complex N-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US10059770B2 (en) 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition
WO2013114167A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of obtaining glycoform composition
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US20150140608A1 (en) * 2012-06-01 2015-05-21 Momenta Pharmaceuticals, Inc. Methods related to omalizumab
US9695244B2 (en) 2012-06-01 2017-07-04 Momenta Pharmaceuticals, Inc. Methods related to denosumab
US20150158943A1 (en) * 2012-06-01 2015-06-11 Momenta Pharmaceuticals, Inc. Methods related to adalimumab
EP2856158A4 (en) * 2012-06-01 2016-06-08 Momenta Pharmaceuticals Inc PROCEDURE RELATED TO RITUXIMAB
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
WO2014179601A2 (en) 2013-05-02 2014-11-06 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015069943A1 (en) * 2013-11-06 2015-05-14 L & J Biosciences Inc. Continuously controlled hollow fiber bioreactor
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
RU2642285C1 (ru) * 2014-01-29 2018-01-24 ЭлДжи КЕМ, ЛТД. Способ получения целевого антитела с модулированным галактозилированием (варианты) и способ модулирования галактозилирования целевого антитела (варианты) путем оптимизации культуральной среды
PL3227454T3 (pl) 2014-12-01 2020-07-27 Amgen Inc. Sposób manipulowania poziomem zawartości glikanów w glikoproteinie
JP2018532429A (ja) 2015-10-26 2018-11-08 ロンザ リミテッド バイオ医薬品を生産するための製造設備
WO2017117218A1 (en) 2015-12-30 2017-07-06 Momenta Pharmaceuticals, Inc. Methods related to biologics
US11377677B2 (en) 2016-03-02 2022-07-05 Lonza Ltd Fermentation process
EP3426217B1 (en) * 2016-03-10 2025-01-15 Lonza Ltd Customizable facility
US10689873B2 (en) 2016-03-10 2020-06-23 Lonza Ltd Customizable facility
EA201892695A1 (ru) 2016-06-03 2019-05-31 Лонза Лимитед Одноразовый биореактор
JP2019517272A (ja) 2016-06-10 2019-06-24 ロンザ リミテッドLonza Limited タンパク質の安定化方法
CN109312291A (zh) 2016-06-24 2019-02-05 隆萨有限公司 可变直径生物反应器
IL264374B2 (en) 2016-08-02 2024-03-01 Lonza Ag Customizable facility
WO2018092000A1 (en) 2016-11-17 2018-05-24 Lonza Ltd. Filter moving device
WO2018093854A1 (en) 2016-11-17 2018-05-24 Lonza Ltd. Filter assembly with filter lock design
CN110192053B (zh) 2016-12-09 2021-10-15 龙沙有限公司 生物反应器的破裂盘及其使用方法
US11034721B2 (en) 2016-12-09 2021-06-15 Lonza Ltd Method for the reduction of viral titer in pharmaceuticals
CA3050477A1 (en) 2017-01-18 2018-07-26 Lonza Ltd Methods for evaluating monoclonality
EP3565908A1 (en) 2017-02-03 2019-11-13 Lonza Ltd Methods of analyzing pluralities of cells and detecting protein sequence variants in biological product manufacturing
EP3565883A1 (en) 2017-02-10 2019-11-13 Lonza Ltd Cell culture system and method
WO2018150271A1 (en) 2017-02-17 2018-08-23 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
JP7252896B2 (ja) 2017-02-17 2023-04-05 ロンザ リミテッド 生物学的産物バリアントを産生する方法
JP7467119B2 (ja) 2017-02-17 2024-04-15 ロンザ リミテッド 発現困難タンパク質のための多部位ssi細胞
US10244406B2 (en) 2017-03-07 2019-03-26 Lonza Ltd. Wireless sensor information monitoring
JP7780858B2 (ja) 2017-06-16 2025-12-05 ロンザ リミテッド 生物製剤の製造のためのユニバーサル自己調節性哺乳動物細胞株プラットフォーム
WO2019067966A1 (en) 2017-09-29 2019-04-04 Lonza Ltd. INFUSION APPARATUS FOR USE IN BIOREACTOR SYSTEMS
IL273549B2 (en) 2017-10-06 2023-10-01 Lonza Ag Automated control of cell culture using Raman spectroscopy
CA3083124A1 (en) 2017-11-20 2019-05-23 Lonza Ltd. Process and system for propagating cell cultures while preventing lactate accumulation
CN108052801B (zh) * 2017-11-30 2020-06-26 中国科学院计算技术研究所 一种基于正则表达式的n糖结构库构建方法与系统
WO2019113050A1 (en) 2017-12-05 2019-06-13 Lonza Ltd Methods of assaying tropolone
JP7108036B2 (ja) 2018-02-02 2022-07-27 ロンザ リミテッド 細胞選択方法及び細胞代謝改変方法
CA3093853A1 (en) 2018-03-26 2019-10-03 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
US12071607B2 (en) 2018-06-01 2024-08-27 Lonza Ltd. Midscale model for organic growth and phasing
WO2020014618A1 (en) 2018-07-13 2020-01-16 Lonza Ltd Methods for improving production of biological products by reducing the level of endogenous protein
WO2020028616A1 (en) 2018-08-02 2020-02-06 Lonza Ltd Methods for manufacturing recombinant protein comprising a disulfide bond
US11884428B2 (en) 2018-08-09 2024-01-30 Lonza Ltd. Transfer station for API seed crystals
EP3833688A1 (en) * 2018-08-10 2021-06-16 Genentech, Inc. Cell culture strategies for modulating protein glycosylation
EP3841193A1 (en) 2018-08-21 2021-06-30 Lonza Ltd. A process for creating reference data for predicting concentrations of quality attributes
US20220049275A1 (en) 2018-10-01 2022-02-17 Lonza, Ltd. Ssi cells with predictable and stable transgene expression and methods of formation
CN113438953A (zh) 2018-10-11 2021-09-24 动量制药公司 采用高度唾液酸化IgG组合物的治疗
EP3906257A4 (en) 2018-12-31 2022-09-14 Momenta Pharmaceuticals, Inc. USTEKINUMAB PRODUCTION PROCESSES
CN113260698B (zh) 2019-02-11 2024-06-25 龙沙有限公司 缓冲剂配制方法和系统
EP3906249A1 (en) 2019-12-06 2021-11-10 Regeneron Pharmacetucals, Inc. Anti-vegf protein compositions and methods for producing the same
US20220389363A1 (en) 2020-01-10 2022-12-08 Lonza Walkersville, Inc. Filter Apparatus and Method for Purifying Biological Processes and Cell Populations
KR20230008830A (ko) 2020-05-08 2023-01-16 리제너론 파마슈티칼스 인코포레이티드 Vegf 트랩 및 미니-트랩 및 안구 장애 및 암의 치료 방법
CN116601288A (zh) 2020-12-18 2023-08-15 龙沙生物股份有限公司 用于生物处理系统的无菌断开连接以及其使用方法

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448884A (en) 1982-03-03 1984-05-15 Kms Fusion, Inc. Glass-surface microcarrier for growth of cell cultures
US5135853A (en) 1983-07-22 1992-08-04 Rensselaer Polytechnic Institute Three compartment bioreactor and method of use
US4764471A (en) 1984-01-04 1988-08-16 Nabisco Brands, Inc. Continuous bioreactor and process
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US5231185A (en) 1985-11-19 1993-07-27 Cornell Research Foundation, Inc. Monosaccharide analog-based glycosidase inhibitors
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
JPH0667317B2 (ja) * 1988-09-21 1994-08-31 財団法人野田産業科学研究所 N−アセチルヘキソサミンデヒドロゲナーゼ、その製造法及び該酵素を用いるn−アセチルグルコサミン又はn−アセチルガラクトサミンの定量法及びその定量用キット
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
SK282950B6 (sk) 1990-04-24 2003-01-09 Biota Scientific Management Pty Ltd Deriváty alfa-D-neuramínovej kyseliny, spôsob ich prípravy, ich použitie a farmaceutické prípravky na ich báze
AU668505B2 (en) 1991-03-18 1996-05-09 Scripps Research Institute, The Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
EP0785988A1 (en) * 1993-07-15 1997-07-30 Neose Pharmaceuticals, Inc Method of synthesizing saccharide compositions
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
TW479061B (en) 1993-12-24 2002-03-11 Mitsubishi Chem Corp Sialic acid derivatives
US5567684A (en) 1994-09-14 1996-10-22 The Regents Of The University Of California Synthetic ganglioside derivatives
US20030143204A1 (en) 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
US6156570A (en) 1997-03-20 2000-12-05 Regents Of The University Of Minnesota Process for the continuous culture of cells
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
PL344391A1 (en) 1998-05-07 2001-11-05 Transkaryotic Therapies Genomic sequences upstream of the coding region of the g-csf gene for protein production and delivery
PL343732A1 (en) 1998-05-07 2001-09-10 Transkaryotic Therapies Modifying the expression of the fsh beta gene by homologous recombination
US6949372B2 (en) * 1999-03-02 2005-09-27 The Johns Hopkins University Engineering intracellular sialylation pathways
AU778046B2 (en) * 1999-04-26 2004-11-11 Genentech Inc. Cell culture process for glycoproteins
ES2217031T3 (es) 1999-12-28 2004-11-01 Iso Tis N.V. Medio de cultivo de celulas que contiene factores de crecimiento y l-glutamina.
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
WO2002002793A1 (fr) * 2000-07-05 2002-01-10 Japan As Represented By Secretary Of Osaka University Processus de production de glycoproteine
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6544788B2 (en) 2001-02-15 2003-04-08 Vijay Singh Disposable perfusion bioreactor for cell culture
JP2005509403A (ja) * 2001-03-27 2005-04-14 スミスクライン・ビーチャム・コーポレイション IgGにおけるグリコフォームの制御
CA2459040A1 (en) * 2001-09-14 2003-03-27 Mimeon, Inc. Methods of making glycolmolecules with enhanced activities and uses thereof
ATE430580T1 (de) * 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US7556944B2 (en) 2002-05-03 2009-07-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing siRNAs
JP4339852B2 (ja) 2002-08-12 2009-10-07 ニュー・イングランド・バイオラブズ・インコーポレイティッド 遺伝子サイレンシングに関する方法および組成物
EP1467299A3 (en) * 2003-03-28 2005-02-09 Solutia Inc. Methods and structure for automated active pharmaceuticals development
EP2338333B1 (en) * 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
US7407810B2 (en) 2003-09-04 2008-08-05 Momenta Pharmaceuticals, Inc. Methods and apparatus for characterizing polymeric mixtures
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006107990A2 (en) * 2005-04-05 2006-10-12 The Johns Hopkins University Improving protein n-glycosylation of eukaryotic cells using dolichol-linked oligosaccharide synthesis pathway, other n-gylosylation-increasing methods, and engineered hosts expressing products with increased n-glycosylation
WO2006109781A1 (ja) * 2005-04-11 2006-10-19 Kyowa Hakko Kogyo Co., Ltd. 糖タンパク質組成物の製造方法
EP1913385B1 (en) * 2005-07-11 2013-08-21 Glykos Finland Oy Tissue carbohydrate compositions and analysis thereof
US20070017758A1 (en) * 2005-07-20 2007-01-25 Or Siu W Magnetorheological damper and use thereof
WO2008000918A1 (en) * 2006-06-29 2008-01-03 Suomen Punainen Risti, Veripalvelu Novel cellular glycan compositions
DE202006008733U1 (de) * 2006-05-31 2007-10-11 Dolmar Gmbh Bremsbandhalterung
US20100173323A1 (en) * 2006-06-09 2010-07-08 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
RU2518289C2 (ru) * 2006-09-13 2014-06-10 Эббви Инк, Способ получения антитела или его фрагмента с подпиткой (варианты)
MX2009004351A (es) * 2006-10-27 2009-05-12 Abbott Biotech Ltd Anticuerpos anti-htnfalfa cristalinos.
GB0624092D0 (en) * 2006-12-01 2007-01-10 Seos Ltd Image display apparatus
WO2008077889A1 (en) * 2006-12-22 2008-07-03 Ares Trading S.A. Analytical method for analyzing c-terminus truncation
CA3069431A1 (en) * 2007-04-03 2008-10-09 Oxyrane Uk Limited Glycosylation of molecules
JP5552421B2 (ja) * 2007-04-16 2014-07-16 モメンタ ファーマシューティカルズ インコーポレイテッド エキソグリコシダーゼを用いるn−グリカンの特性決定法
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
KR20110084196A (ko) * 2008-09-26 2011-07-21 유레카 쎄라퓨틱스, 인코포레이티드 다양한 글리코실화 패턴을 가진 세포계 및 단백질
US11520643B2 (en) * 2008-12-03 2022-12-06 International Business Machines Corporation Clipboard object sharing for instant messaging
JP4892051B2 (ja) * 2009-11-30 2012-03-07 株式会社東芝 電子機器、及び機能設定データ設定方法
US8524217B2 (en) * 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
US9677105B2 (en) * 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) * 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture

Also Published As

Publication number Publication date
AU2008240080A1 (en) 2008-10-23
PL2137655T3 (pl) 2012-12-31
JP2010524467A (ja) 2010-07-22
EP2528002A3 (en) 2013-04-03
US20160097074A1 (en) 2016-04-07
CA2682738A1 (en) 2008-10-23
CN101681396A (zh) 2010-03-24
US20100113294A1 (en) 2010-05-06
ES2389618T3 (es) 2012-10-29
EP2528002A2 (en) 2012-11-28
RU2009141965A (ru) 2011-05-27
EP2137655B1 (en) 2012-07-11
EP2137655A1 (en) 2009-12-30
PT2137655E (pt) 2012-09-14
EP2528002B1 (en) 2015-11-04
WO2008128227A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
BRPI0810471A2 (pt) Produtos de glicoproteína definidos e métodos relacionados
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
UA14280S (uk) Футляр для косметичного виробу
EP2122054A4 (en) NONWOVEN PANEL AND PRODUCTION METHOD THEREOF
BRPI0813753A2 (pt) Produto pré-impregnado
BRPI0817890A2 (pt) Folha e artigo
ATE547013T1 (de) Natürliche getränkeprodukte
BRPI0908130A2 (pt) Produto
FI20075978A0 (fi) Järjestely ja menetelmä
BRPI0907890A2 (pt) Implantes lacrimais e métodos relacionados
BRPI0817082A2 (pt) Implantes lacrimais e métodos relacionados
ATE531278T1 (de) Süsswaren-produkt
BRPI0810706A2 (pt) Produtos rotacionalmente moldados e moldes.
BRPI0907768A2 (pt) Poltrona e guarnição
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.
DE602008003371D1 (de) ewandelter Artikel
BRPI0814876A2 (pt) Análogos de pirona fosforilados e métodos
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
BRPI0913642A2 (pt) produtos de combinação
BRPI0908183A2 (pt) membro embalado e método de produção do mesmo
BRPI0914151A2 (pt) distribuidor de medicamento e método
FI20090142A0 (fi) Uudet menetelmät ja tuotteet
FI20060795A0 (fi) Kylläisyyttä aiheuttava tuote
ATE475602T1 (de) AUSGIEßER
BRPI0716494A2 (pt) Produto alimentício proteico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.